MassARRAY spectrometry is more sensitive than PreTect HPV-Proofer and consensus PCR for type-specific detection of high-risk oncogenic human papillomavirus genotypes in cervical cancer

Journal of Clinical Microbiology

Volumn 49, Issue 10, 2011, Pages 3537-3544

  Basu, Partha ^a   Chandna, Puneet ^b   Bamezai, R N K ^c   Siddiqi, Maqsood ^d   Saranath, Dhananjaya ^e   Lear, Adrian ^f   Ratnam, Sam ^g,h  

^a CHITTARANJAN NATIONAL CANCER INSTITUTE   (India)

^b AceProbe Technologies (India) Pvt Ltd   (India)

^c JAWAHARLAL NEHRU UNIVERSITY   (India)

^d Cancer Foundation of India   (India)

^e RELIANCE LIFE SCIENCES PVT LTD   (India)

^f Dr H Bliss Murphy Cancer Centre   (Canada)

^g Newfoundland and Labrador Public Health Laboratory   (Canada)

^h Public Health Laboratory   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; PROTEIN E6; PROTEIN E7;

ADULT; ANALYTIC METHOD; ARTICLE; CANCER RISK; CANCER STAGING; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; GENOTYPE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 31; HUMAN PAPILLOMAVIRUS TYPE 33; HUMAN PAPILLOMAVIRUS TYPE 35; HUMAN PAPILLOMAVIRUS TYPE 39; HUMAN PAPILLOMAVIRUS TYPE 45; HUMAN PAPILLOMAVIRUS TYPE 51; HUMAN PAPILLOMAVIRUS TYPE 52; HUMAN PAPILLOMAVIRUS TYPE 56; HUMAN PAPILLOMAVIRUS TYPE 58; HUMAN PAPILLOMAVIRUS TYPE 59; HUMAN PAPILLOMAVIRUS TYPE 66; HUMAN PAPILLOMAVIRUS TYPE 68; HUMAN PAPILLOMAVIRUS TYPE 73; HUMAN TISSUE; MAJOR CLINICAL STUDY; MASS SPECTROMETRY; NONHUMAN; NUCLEOTIDE SEQUENCE; PAPILLOMAVIRUS INFECTION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; STRAIN IDENTIFICATION; TUMOR VIRUS; UTERINE CERVIX CANCER; VIRUS DETECTION; VIRUS IDENTIFICATION; VIRUS STRAIN; WART VIRUS;

ADULT; COINFECTION; FEMALE; GENOTYPE; HUMANS; MIDDLE AGED; MOLECULAR DIAGNOSTIC TECHNIQUES; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; SENSITIVITY AND SPECIFICITY; SPECTRUM ANALYSIS; UTERINE CERVICAL NEOPLASMS; VIROLOGY;

HUMAN PAPILLOMAVIRUS; HUMAN PAPILLOMAVIRUS TYPE 16;

EID: 80053559972     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.00354-11     Document Type: Article

References (27)

1. Basu, P., et al. 2009. Human papillomavirus genotype distribution in cervical cancer in India: results from a multi-center study. Asian Pac. J. Cancer Prev. 10:27-34.
2. Bosch, F. X., et al. 2008. Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia. Vaccine 26S:K1-K16.
3. Bouvard, V., et al. 2009. Special report: policy. A review of human carcinogens - Part B: biological agents. Lancet 10:321-322.
4. Castle, P. E., et al. 2008. Human papillomavirus genotype specificity of Hybrid Capture 2. J. Clin. Microbiol. 46:2595-2604.
5. Choi, Y. D., W. W. Jung, J. H. Nam, H. S. Choi, and C. S. Park. 2005. Detection of HPV genotypes in cervical lesions by the HPV DNA chip and sequencing. Gynecol. Oncol. 98:369-375.
6. Cogliano, V., et al. 2005. Carcinogenicity of human papillomaviruses. Lancet Oncol. 6:204. (Pubitemid 40450709)
7. Cuschieri, K. S., et al. 2005. Persistent high risk HPV infection associated with development of cervical neoplasia in a prospective population study. J. Clin. Pathol. 58:946-950. (Pubitemid 41265279)
8. Cuzick, J., et al. 2008. Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries. Vaccine 26S:K29-K41.
9. Cuzick, J., et al. 2006. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int. J. Cancer 119:1095-1101. (Pubitemid 44116919)
10. Dillner, J., M. Arbyn, and L. Dillner. 2007. Translational mini review series on vaccines: monitoring of human papillomavirus vaccination. Clin. Exp. Immunol. 148:199-207. (Pubitemid 46591311)
11. Dockter, J., et al. 2009. Clinical performance of the APTIMA® HPV Assay for the detection of high-risk HPV and high-grade cervical lesions. J. Clin. Virol. 45:S55-S61.
12. Ginocchio, C. C., D. Barth, and F. Zhang. 2008. Comparison of the third wave invader human papillomavirus (HPV) assay and the Digene HPV Hybrid Capture 2 assay for detection of high-risk HPV DNA. J. Clin. Microbiol. 46:1641-1646. (Pubitemid 351657207)
13. Gravitt, P. E., et al. 2008. New technologies in cervical cancer screening. Vaccine 26:K42-K52.
14. Khan, M. J., et al. 2005. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J. Natl. Cancer Inst. 97:1072-1079. (Pubitemid 41417924)
15. Lie, A. K., et al. 2005. DNA-versus RNA-based methods for human papillomavirus detection in cervical neoplasia. Gynecol. Oncol. 97:908-915. (Pubitemid 40824665)
16. Molden, T., I. Kraus, H. Skomedal, T. Nordstrøm, and F. Karlsen. 2007. PreTect™ HPV-Proofer: real-time detection and typing of E6/E7 mRNA from carcinogenic human papillomaviruses. J. Virol. Methods 142:204-212. (Pubitemid 46590424)
17. Munagala, R., et al. 2009. Significance of multiple HPV infection in cervical cancer patients and its impact on treatment response. Int. J. Oncol. 34:263-271.
18. Muñoz, N., et al. 2003. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N. Engl. J. Med. 348:518-527. (Pubitemid 36159887)
19. Nygren, A. O., et al. 2010. Quantification of fetal DNA by use of methylationbased DNA discrimination. Clin. Chem. 56:1627-1635.
20. Patel, D. A., et al. 2009. Development and evaluation of a PCR and mass spectroscopy-based (PCR-MS) method for quantitative, type-specific detection of human papillomavirus. J. Virol. Methods 160:78-84.
21. Qu, S., et al. 15 Jan 2011, posting date. A comparison of matrix-assisted laser desorption/ionization time-of-flight mass spectrometry and surface plasmon resonance for genotyping of high-risk human papillomaviruses. Intervirology. doi:10.1159/000322722.
22. Ratnam, S., et al. 2010. Clinical performance of the PreTect HPV-Proofer E6/E7 mRNA assay in comparison with that of Hybrid Capture 2 test for identification of women at risk of cervical cancer. J. Clin. Microbiol. 48:2779-2785.
23. Serrano, M. L., M. Correa, O. Medina, D. Melgarejo, and M. M. Bravo. 2003. Tipificación de vírus del papiloma humano mediante secuencia directa em mujeres com citologia normal. Rev. Colomb. Cancer 7:18-24.
24. Soderlund-Strand, A., J. Dillner, and J. Carlson. 2008. High-throughput genotyping of oncogenic human papillomaviruses with MALDI-TOF mass spectrometry. Clin. Chem. 54:86-92. (Pubitemid 351182600)
25. Szarewski, A., et al. 2008. Comparison of predictors for high-grade cervical intraepithelial neoplasia in women with abnormal smears. Cancer Epidemiol. Biomarkers Prev. 17:3033-3042.
26. Vernon, S. D., E. R. Unger, and D. Williams. 2000. Comparison of human papillomavirus detection and typing by cycle sequencing, line blotting, and hybrid capture. J. Clin. Microbiol. 38:651-655. (Pubitemid 30082658)
27. Yang, H., et al. 2005. Sensitive detection of human papillomavirus in cervical, head/neck, and schistosomiasis-associated bladder malignancies. Proc. Natl. Acad. Sci. U. S. A. 102:7683-7688. (Pubitemid 40741031)